🔗 Visit the ClinicalTrials.gov page for NCT01306890
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Perspectives on treatment of metastatic castration-resistant prostate cancer. | Oncologist | 2013 | 1.42 |
| 2 | Prostate cancer vaccines: Update on clinical development. | Oncoimmunology | 2013 | 0.98 |
| 3 | Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. | Cancer Immunol Immunother | 2015 | 0.82 |
| 4 | Immune response to sipuleucel-T in prostate cancer. | Cancers (Basel) | 2012 | 0.79 |
| 5 | Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. | Oncoimmunology | 2015 | 0.78 |
| 6 | Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. | Future Oncol | 2016 | 0.75 |